Aiderbio combines the patented Port Pocket™ 3D cell culture kit with our AI-based fluorescence-image toxicity prediction system — built for pharma, biotech, and CROs that need reproducible, quantitative early-stage drug evaluation.
Most drug candidates that pass animal testing fail in clinical trials. The world is shifting toward Non-Animal Methods (NAMs), yet existing 3D cell cultures suffer from poor reproducibility, low cell recovery, and inconsistent results — limiting their use in real drug evaluation pipelines.
A platform built from the ground up to standardize 3D cell evaluation — from culture, to image, to decision.
A patented hybrid single-well design that stabilizes organoid position and prevents loss during media exchange.
End-to-end pipeline turning Live/Dead fluorescence images into three quantitative drug-response indicators.
Contract organoid culture and AI-based drug response analysis for pharma, biotech, and CRO partners.
Each technology was designed to solve a specific pain point in 3D drug evaluation — together they form a fully integrated discovery pipeline.
Conventional 3D plates lose cells during media exchange and yield variable recovery. The hybrid hexagonal micro-pocket geometry — combining Gri3D-style array and 4Dcell-style anchor pillars — physically retains organoids in place, dramatically improving reproducibility.
A purpose-built end-to-end pipeline. Fluorescence images of Live/Dead-stained cells are processed by our AI segmentation engine, embedded into quantitative feature vectors, and translated into the three indicators teams actually need: migration, apoptosis, and toxicity.
All performance figures are based on Aiderbio's internal evaluation and product positioning materials.
| Metric | Aiderbio Port Pocket™ | Conventional 3D Plate | Hydrogel Kit |
|---|---|---|---|
| Experimental CV | 10 – 15% | 20 – 30% | 25 – 40% |
| Cell Recovery | 70 – 85% | 50 – 70% | 40 – 60% |
| Dropout Rate | 5 – 10% | 15 – 30% | 25 – 50% |
| Integrated AI Analytics | Built-in | None | None |
Two hardware formats and one AI software service — designed to be used together or independently.
Our flagship product line. Hexagonal micro-pocket geometry plus anchor pillars keep organoids in place throughout the experiment, delivering industry-leading reproducibility.
Cloud-ready AI analytics that converts Live/Dead fluorescence images into quantitative migration, apoptosis, and toxicity indicators — automatically.
Our R&D operates inside the J-BioValley Center in Jeonju, with dedicated wet-lab and engineering space. Hardware iterations, organoid culture, and AI pipeline development happen under one roof — so design and biology stay tightly coupled.
Drug development is shifting away from animal testing — and 3D cell technologies are leading the way.
Global drug development technology market projected to 2030.
Global animal-testing alternatives market projected to 2035.
Market size for scaffold-free 3D cell culture technology.
Each milestone is anchored to real customers, real validation data, and real revenue.
Engineering, biomedical, ophthalmology, and physics — the team behind Aiderbio is purpose-built for the challenge.
Founder · Chief Executive Officer
MD · Retina Specialist · Clinical Advisor
Ph.D., Physics · KIST Senior Researcher
Ph.D., Mechanical Engineering · Assistant Professor
Manager · Business & Operations
Research Associate · Cell Culture
We work with pharmaceutical companies, biotech ventures, CROs, hospitals, and academic research labs. Drop us a note and our team will reach out within 1–2 business days.